Treating to Target in Patients with Gout and Chronic Kidney DiseasePremiere Date: Tuesday, November 1, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Nurse Practitioners (AANP)
- Physician Assistants (AAPA)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, November 1, 2017
Note: Credit Is No Longer Available
|Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Hospital for Special Surgery
New York, NY
|Robin K. Dore, MD
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA
|Eva Hardy, MS, RN, ANP-BC
Department of General Orthopedic Surgery
Presbyterian Health Services
Presbyterian Rust Medical Center
Rio Rancho, NM
Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with CKD constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.
Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and chronic kidney disease (CKD).
Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.
Mandell B, Keenan R. So you think you know gout? Fresh perspectives on hyperuricemia for today’s complicated patients. Medscape Website. http://www.medscape.org/viewarticle/837667. Published January 30, 2015. Accessed October 16, 2016.
At the end of this CE activity, participants should be able to:
- Execute strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD.
- Utilize educational resources in shared decision-making discussions with patients to promote medication adherence and optimize outcomes.
- Implement strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD.
- Describe ways to engage patients with gout and CKD in discussions of gout education and medication adherence.
- Assess strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals with an interest in gout and chronic kidney disease.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Credit (Nurse Practitioners):
This program is approved for 1.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Program ID 16102399. This program was planned in accordance with AANP CE Standards and Policies.(Effective 12/9/16)
AAPA Credit (Physician Assistants):
This program has been reviewed and is approved for a maximum of 1.5 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 11/22/2016. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number:
0376-0000-16-028-L01-P (live program)
0376-0000-16-028-H01-P (enduring program)
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Robin K. Dore, MD has disclosed she received research support from AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Pfizer Inc. and UCB, Inc. She serves on speakers bureau for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; Sanofi-Genzyme; Takeda Pharmaceuticals U.S.A., Inc. and UCB, Inc. She serves as consultant for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company and Sanofi-Genzyme.
Allan Gibofsky, MD, JD, MACR, FACP, FCLM has disclosed he serves on speakers bureau for AbbVie Inc.; Amgen Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc. and UCB, Inc. He serves as consultant for AbbVie; Amgen Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder in AbbVie Inc.; Amgen Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc. and Regeneron Pharmaceuticals, Inc.
Eva Hardy, MS, RN, ANP-BC has no disclosures to report
Jeffrey Helfand, DO, MD (peer reviewer) has no disclosures to report.
Scott Richards, PhD, PA-C, DFAAPA (peer reviewer) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report
Daniela V. DiBiase, MS (planning committee) has no disclosures to report
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals U.S.A., Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).